BioVentures MedTech Funds is committed to the innovators who are changing the practice of medicine. BioVentures MedTech Funds invests in companies that are developing today’s leading-edge medical technologies, finding the dynamic solutions that improve healthcare outcomes worldwide.BioVentures MedTe
Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Series C
Portfolio 9
| Date | Name | Website | Total Raised | Location |
| 09.08.2023 | Georgiamun... | georgiamune.com | $75M | - |
| 14.07.2016 | Endotronix | endotronix.com | $159M | United Sta... |
| - | OPTIVIO | optivio.com | - | United Sta... |
| - | CoNextions... | conextionsmed.com | - | United Sta... |
| - | Unified In... | uidevices.com | $2.46M | United Sta... |
| - | CareSignal | caresignal.health | - | United Sta... |
| - | Verax Biom... | veraxbiomedical.com | $12M | - |
| - | BRAINBox S... | brainboxinc.com | $23M | United Sta... |
| - | Sonomotion | sonomotion.com | $22.4M | United Sta... |
Persons 4
| Date | First Name | Last Name | Title | Location | |||
| - | Jonathan | Cohen | Keystone P... | - | - | - | |
| - | Chris | Thompson | Keystone P... | - | - | - | |
| - | Tom | Buttacavol... | Managing D... | - | - | - | |
| - | Stephen | Liu, MD | Venture Pa... | - | - | - |
Mentions in press and media 12
| Date | Title | Description |
| 19.02.2020 | Endotronix Enrolls First Patients in PROACTIVE-HF Pivotal Trial | LISLE, Ill. /PRNewswire/ — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal ... |
| 01.10.2019 | Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution | LISLE, IL – Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The ... |
| 14.09.2018 | Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure | Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health... |
| 08.10.2016 | BioVentures Investors Closes Fund IV at $87M | BioVentures Investors, a Wellesley, Massachusetts-based venture capital firm focused on medtech, closed its fourth fund, at $87m. Led by Marc Goldberg and Peter Feinstein, founders, Jeff Barnes, Managing Director and Partner, and Walter Gil... |
| 05.08.2016 | BioVentures Investors Holds First Close of 4th Medtech Venture Capital Fund, at $29.3M | BioVentures Investors, a Wellesley, MA-based venture capital firm focused on medtech, held the first close of its fourth fund, at $29.3m. According to a regulatory form filed with the SEC, BioVentures Investors IV Limited Partnership has a ... |
| 17.07.2016 | Endotronix Raises $32M Series C from Aperture Venture Partners | Endotronix, Inc., a digital health medtech company providing innovative solutions for patients with advanced heart failure, announced that the company has closed a $32 million Series C round of financing. The investor syndicate brings toget... |
| 17.07.2016 | Endotronix Raises $32M Series C from BioVentures Investors | Endotronix, Inc., a digital health medtech company providing innovative solutions for patients with advanced heart failure, announced that the company has closed a $32 million Series C round of financing. The investor syndicate brings toget... |
| 14.07.2016 | Endotronix Closes $32 Million in Financing to Address Heart Failure Management | WOODRIDGE, Ill., July 14, 2016 /PRNewswire/ — Endotronix, Inc., a digital health medtech company providing innovative solutions for patients with advanced heart failure, today announced that the company has closed a $32 million Series C rou... |
| 10.02.2015 | Looks like BioVentures is in the midst of raising a new $100M fund | The venture firm typically invests $3 million to $10 million, it says, and does operate like your typical VC, however: “Generally, we like to see a business plan that calls for total capital requirement of $15 million to $20 million to reac... |
| 25.07.2012 | Fundraising: Percutaneous mitral valve repair company raises $14.8 million | Industry: Medical Devices Products: Developing PerCu-Pro System that is an implanted device to percutaneously repair the mitral valve to prevent blood leaking into the left ventricle (also known as mitral valve regurgitation); the Dexterity... |
Show more